TAVO605 / Tavotek - LARVOL DELTA

TAVO605, a novel CD318 (CDCP1) ADC, for the treatment of solid cancers that are non-responding or resistant to Enhertu treatment (AACR 2025) - "By targeting a novel tumor associated antigen CD318 (CDCP1) with high expression in multiple major solid tumors, our lead CD318-ADC molecule (TAVO605) showed potent cytotoxicity to multiple tumor cell lines as well as in CDX and PDX solid tumor xenograft models. CD318-ADC was tolerable and will be further evaluated in preclinical monkey toxicity studies. Our data supported the further development of TAVO605 as a potent therapy for solid tumors non-responding or resistant to current available treatments, e.g., by Enhertu, especially in tumors with low or no HER2 expression such as triple negative breast cancers."

Bladder Cancer • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • CDCP1 • HER-2